Form 4: Oncology Institute COO Jeremy Castle Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Chief Operating Officer of Oncology Institute, Jeremy Castle, reports acquisition and disposal of common stock and RSU awards.
Summary
- Jeremy Castle, the Chief Operating Officer of Oncology Institute, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
- On March 31, 2025, Castle acquired 162,281 shares of common stock at $0.
- On the same date, Castle disposed of 252,667 shares of common stock.
- The filing also mentions RSU awards that vest over four years, with 1/4th vesting on the first anniversary of the Vesting Commencement Date and the remaining vesting in three equal annual installments.
Sentiment
Score: 5
Explanation: This is a routine filing of stock transactions by an insider, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report changes in their ownership of company stock, ensuring transparency and compliance with SEC regulations.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of transaction involving common stock acquisition and disposal. |
| 04/02/2025 | Date of signature on the report. |
Keywords
Form 4, Beneficial Ownership, Oncology Institute, TOI, Jeremy Castle, COO, RSU, Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.